GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aequus Pharmaceuticals Inc (TSXV:AQS) » Definitions » Change In Receivables

Aequus Pharmaceuticals (TSXV:AQS) Change In Receivables : C$0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Aequus Pharmaceuticals Change In Receivables?

Aequus Pharmaceuticals's change in receivables for the quarter that ended in Sep. 2024 was C$0.06 Mil. It means Aequus Pharmaceuticals's Accounts Receivable declined by C$0.06 Mil from Jun. 2024 to Sep. 2024 .

Aequus Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was C$0.28 Mil. It means Aequus Pharmaceuticals's Accounts Receivable declined by C$0.28 Mil from Dec. 2022 to Dec. 2023 .

Aequus Pharmaceuticals's Accounts Receivable for the quarter that ended in Sep. 2024 was C$0.06 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Aequus Pharmaceuticals's Days Sales Outstanding for the three months ended in Sep. 2024 was 34.53.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Aequus Pharmaceuticals's liquidation value for the three months ended in Sep. 2024 was C$-6.96 Mil.


Aequus Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Aequus Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aequus Pharmaceuticals Change In Receivables Chart

Aequus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 -0.22 -0.17 0.62 0.28

Aequus Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 0.04 - -0.08 0.06

Aequus Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aequus Pharmaceuticals  (TSXV:AQS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Aequus Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.056/0.148*91
=34.53

2. In Ben Graham's calculation of liquidation value, Aequus Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Aequus Pharmaceuticals's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.025-7.078+0.75 * 0.056+0.5 * 0.099
=-6.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aequus Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Aequus Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Aequus Pharmaceuticals Business Description

Traded in Other Exchanges
Address
200 Granville Street, Suite 2820, Vancouver, BC, CAN, V6C 1S4
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The Company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products, namely Tacrolimus IR and Vistitan.
Executives
Doug Janzen Director, Senior Officer

Aequus Pharmaceuticals Headlines

No Headlines